

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Elsbernd Brian</u> <hr/> (Last) (First) (Middle) 355 ALHAMBRA CIRCLE SUITE 1250 <hr/> (Street) CORAL FL 33134 GABLES <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/27/2018	3. Issuer Name and Ticker or Trading Symbol <u>CATALYST PHARMACEUTICALS, INC. [ CPRX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Compliance/Legal Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	-------------------------------------------------------	----------------------------------------------------------	-------------------------------------------------------

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Options to purchase Common Stock	(1)	02/16/2023	Common Stock 65,000	1.85	D	
Options to purchase Common Stock	(2)	06/15/2023	Common Stock 40,000	0.79	D	
Options to purchase Common Stock	(3)	01/03/2024	Common Stock 50,000	1.13	D	
Options to purchase Common Stock	(4)	01/02/2025	Common Stock 60,000	4.01	D	
Options to purchase Common Stock	(5)	12/19/2025	Common Stock 225,000	2.24	D	

**Explanation of Responses:**

- Options have vested or will vest in three equal tranches on February 16, 2017, 2018 and 2019.
- Options vested in two equal tranches on June 16, 2017 and 2018.
- Options have vested or will vest in three equal tranches on January 3, 2018, 2019 and 2020.
- Options will vest in three equal tranches on January 2, 2019, 2020 and 2021.
- Options will vest in three equal tranches on December 19, 2019, 2020 and 2021.

/s/ Brian Elsbernd 01/04/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.